Ironwood Q1 2026: Revenue $107M (+159% YoY); GAAP EPS $0.25 from -$0.23; LINZESS sales $273M (+97%)

IRONWOOD PHARMACEUTICALS INC

2026-Q1 EPS reported $0.24 vs consensus $0.24 ▼ miss (-2.0%)

GAAP net income $41M ($0.25 basic EPS) vs loss $37M ($0.23 loss) in Q1 2025.
LINZESS U.S. net sales $273M, up 97% YoY; 5% EUTRx demand growth.
Adjusted EBITDA $77M vs negative $4.7M a year ago.
Maintains full-year 2026 guidance; on track to start apraglutide Phase 3 trial in Q2 2026.
sNDA for LINZESS in pediatric FC (2-5yrs) accepted with priority review; PDUFA May 24.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IRONWOOD PHARMACEUTICALS INC reported first quarter 2026 results: revenue $ 106,506, net income 40,773, EPS 0.25. Guidance reaffirmed.

Period: first quarter 2026
Revenue: $ 106,506
Net income: 40,773
EPS: 0.25
Guidance: reaffirmed
Result: reported results

Exact text from the filing

First Quarter 2026 Financial Highlights 1 (in thousands, except for per share amounts) Q1 2026 Q1 2025 Total revenue $ 106,506 $ 41,143 Total costs and expenses 33,933 70,251 GAAP net income (loss) 40,773 (37,386 ) GAAP net income (loss) – per share basic 0.25 (0.23 ) GAAP net income (loss) – per share diluted 0.24 (0.23 ) Adjusted EBITDA 2 76,671 (4,742 ) Non-GAAP net income (loss) 40,945 (23,228 ) Non-GAAP net income (loss) per share – basic 0.25 (0.14 ) Non-GAAP net income (loss) per share – diluted 0.24 (0.14 )

View on SEC.gov

Browse all earnings releases →

IRONWOOD PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-26-056656

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.